Video Series

Joseph M. Coney, MD, FACS, emphasizes the vital role of community engagement in tackling difference in social determinants of health among patients with diabetes and highlights the significance of multilevel efforts to enhance community health outcomes.

Considerations for growth factor and stem cell transplant for patients with MDS is discussed.

Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome.

Adverse reactions and challenges with patient adherence to therapy are explored by dry eye disease experts.

Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD; explore the current treatment landscape of dry eye disease.

Russell P. Gollard, MD, FACP, explores effective collaboration among health care professionals, administrators, and specialty pharmacies in managing rare diseases like hemophilia A.

Financial considerations associated with heart failure management are dissected.

Barriers to optimal heart failure treatment are broken down by the expert panelists.

Specialists define and discuss extrapolation, along with the importance of strong data in specific disease states.

A medical expert discusses the findings of a randomized trial investigating the use of andexanet alfa versus usual care in patients with acute intracerebral hemorrhage (ICH) and recent direct oral anticoagulant (DOAC) use.

Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023.

An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations.

Siamak Daneshmand, MD, explores unmet needs in the bladder cancer treatment landscape at ESMO 2023.

Financial considerations in MDS treatment are discussed.

Key opinion leaders discuss how patient quality of life is impacted by MDS treatment-associated challenges.

Toxicity management in HCC treatment is discussed by medical experts.

Dr Haumschild leads a discussion surrounding toxicity profiles specifically related to HCC.

Joseph M. Coney, MD, FACS, discusses the crucial role of ongoing community support and active engagement in boosting clinical trial recruitment and emphasizes the importance of establishing trust and increasing visibility to enhance patient confidence in the process.

A key opinion leader provides insight into key HFpEF treatment strategies.

Medical experts discuss strategies to connect with patients to alleviate concerns potentially associated with converting heart failure therapies.

Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.

Medical experts discuss interchangeability designation requirements for biosimilars.

Stuart J Connolly, MD, FRCPC, discusses updated strategies for managing intracerebral hemorrhage, emphasizing the significance of timely diagnosis to improve hemostatic efficacy.

Richard Kim, MD, offers perspective regarding optimal use of health care resources in the management of HCC.

The decision to perform an EGD is evaluated between academic and community health care perspectives.

An expert perspective on the variety of MDS subtypes is provided.

Ryan Haumschild, PharmD, MS, MBA, CPEL, opens the discussion by defining the MDS disease state.